Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Inc. is a company based in Norwood, Massachusetts. They are a privately held company with 57 employees and generate approximately $15 million in annual revenue. Corbus Pharmaceuticals focuses on developing innovative treatments for serious illnesses. Their internal development pipeline includes CRB-701, a next-generation antibody drug conjugate (ADC) targeting Nectin 4 on cancer cells, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. The company is dedicated to pushing the boundaries of scientific research to develop breakthroughs in the field of oncology. They are committed to bringing innovative scientific approaches to well-understood biological pathways to help people defeat serious illness. For more information about Corbus Pharmaceuticals Holdings Inc., please visit their website at corbuspharma.com.